PHA121, the first orally available bradykinin B2-receptor antagonist, shows clinically relevant activity in a translational in vivo model

Pharvaris Uncategorised

Data accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2020 Zug, Switzerland, April 9, 2020 – Pharvaris GmbH, a clinical-stage company focused on the discovery and development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other B2-receptor-mediated indications, announced data from a late-breaking poster planned for presentation at …

Pharvaris Appoints Peng Lu, M.D., Ph.D., as Chief Medical Officer

Pharvaris Uncategorised

Company strengthens executive team with addition of skilled HAE drug developer Leiden, The Netherlands, Feb. 7, 2020 – Pharvaris B.V., a clinical-stage company focused on the discovery and development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other B2-receptor-mediated indications, has appointed Peng Lu, M.D., Ph.D., to the newly-created position of Chief Medical Officer, a …

Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema

Pharvaris Uncategorised

Pharvaris has initiated its first-in-human clinical trial of PHA121 Series B participants led by Foresite Capital with additional new investors Bain Capital Life Sciences, venBio Partners, and Venrock Partners Leiden, The Netherlands, Sept. 10, 2019 – Pharvaris B.V., a clinical-stage company focused on the discovery and development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and …